Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.advisorDe Biase, Chiara-
dc.contributor.advisorCapuano, Ernesto-
dc.contributor.advisorDe Luca, Stefania-
dc.contributor.advisorD’Anna, Carolina-
dc.contributor.advisorLuciano, Rossella-
dc.contributor.advisorPiscione, Federico-
dc.contributor.advisorTrimarco, Bruno-
dc.contributor.advisorGalasso, Gennaro-
dc.identifier.citationDe Biase C, Capuano E, De Luca S, D’Anna C, Luciano R, Piscione F, Trimarco B, Galasso G. Early Surgery after Coronary Revascularization: A Fine Line between Bleeding and Thrombosis. Translational Medicine @ UniSa 2015, 11(3):14-23en_US
dc.description.abstractManagement of PCI patients undergoing early surgery is still a matter of debate. Noteworthy, PCI patients require a dual antiplatelet therapy (DAPT), with aspirine and a thienopiridine (clopidogrel, prasugrel, ticagrelor), because of the high risk of stent thrombosis (ST), myocardial infarction (MI) and death, especially within the first month. Indeed, the number of surgical interventions after PCI is actually increasing, and physicians are looking for the best antiplatelet therapy management, in order to reduce both, bleeding and thrombosis risk. In this paper, current guidelines therapy management and new optional strategies to reduce the cardiovascular risk, related to early surgery, are discussed.en_US
dc.format.extentP. 14-23en_US
dc.sourceUniSa. Sistema Bibliotecario di Ateneoen_US
dc.subjectNon-cardiac surgeryen_US
dc.subjectPercutaneous coronary interventionen_US
dc.subjectAntiplatelet therapyen_US
dc.subjectStent hrombosisen_US
dc.titleEarly Surgery after Coronary Revascularization: A Fine Line between Bleeding and Thrombosisen_US
Appears in Collections:Translational Medicine @ UniSa. Volume 11 (jan.-apr. 2015)

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.